BeOne Medicines (formerly BeiGene) is a global oncology-focused biopharmaceutical company developing and commercializing cancer therapies. Its flagship product BRUKINSA (zanubrutinib), a BTK inhibitor for certain blood cancers, is a core commercial driver alongside a broader pipeline of immuno-oncology and targeted agents. The company runs research and commercial operations across the U.S., China, Europe, and other markets, with a dual emphasis on internal discovery and global clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1,315.3 | — | 94.3 | — |
| Q3 2025 | 1,412.3 | — | 124.8 | — |
| Q4 2025 | 1,498.2 | — | 66.5 | — |
| Q1 2026 | 1,513.4 | — | 227.4 | 20,107.9% |
| Q2 2026 | 1,705.1 | 29.6% | 237 | 151.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Flex Ltd. (FLEX), Microchip Technology Incorporated (MCHP), JD.com, Inc. (JD), Expedia Group, Inc. (EXPE), Vodafone Group Public Limited Company (VOD), MongoDB, Inc. (MDB)